Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 578-skin-graft-except-for-skin-ulcer-or-cellulitis-without-cc-mcc
    Ask Trek AI about this page

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    DRG 578 covers inpatient stays for skin graft procedures excluding skin ulcer or cellulitis and without Major Complication or Comorbidity or Complication or Comorbidity, defining the clinical scope for reimbursement. Proper assignment influences Medicare payment by grouping cases with similar expected resource use and setting the inpatient prospective payment structure.

    Customize your policy alerts

    Sign up for drg 578 policy alerts

    Get alerted when payer policies referencing 578 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 578 Overview

    DRG 578 covers inpatient stays for skin graft procedures excluding cases related to skin ulcer or cellulitis, and without a Major Complication or Comorbidity or a Complication or Comorbidity. This Diagnosis-Related Group encompasses operative management of extensive soft tissue loss requiring grafting, commonly resulting from trauma, burns, or surgical excision of lesions. It matters for Medicare payment because classification into this Diagnosis-Related Group determines base payment rates and resource expectations for the hospitalization. Accurate coding and documentation of the reason for grafting and absence of Major Complication or Comorbidity or Complication or Comorbidity affect reimbursement assignment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute surgical technique and graft integration studies: randomized or prospective cohort studies comparing different skin graft harvest and application techniques (split-thickness vs. full-thickness variations, meshing ratios, fixation methods) in patients undergoing skin grafting for non-ulcer, non-cellulitis indications such as traumatic wounds, burns, or excision of tumors. These trials enroll inpatients at the time of initial operative repair and measure early outcomes such as graft take rate, need for reoperation, infection, length of stay, and immediate postoperative resource utilization, which directly affects hospital reimbursement and DRG-level costs. Understanding which techniques improve graft survival and reduce complications helps providers optimize perioperative protocols and helps payers anticipate acute care costs.
    • Comparative effectiveness studies of adjunctive intra- and perioperative therapies: pragmatic trials or observational comparative studies evaluating adjuncts like negative-pressure wound therapy, topical biologics (e.g., growth factor–containing matrices), or cellular concentrates applied at the time of grafting in diverse inpatient populations (trauma, oncologic resection, reconstructive indications). These studies focus on mid-term endpoints such as time to complete epithelialization, rates of secondary procedures, and readmissions within 30–90 days, informing which adjuncts provide clinically meaningful improvements in healing for patients without ulcer/cellulitis pathology. Results are relevant to surgeons and hospital administrators balancing incremental supply and device costs against potential reductions in downstream resource use and readmission risk under bundled payment or DRG-based reimbursement.
    • Post-discharge functional outcomes and health-services research: longitudinal cohort studies and registries tracking post-discharge outcomes for skin graft recipients, including functional status, scar-related morbidity, wound-related outpatient visits, and long-term need for revision surgery across different patient subgroups (e.g., younger trauma patients vs. older reconstructive cases). This research addresses longer-term utilization, quality-of-life, and rehabilitation needs that are frequently not captured during the index hospitalization but drive total cost of care and program planning for post-acute services. Findings guide discharge planning, outpatient follow-up protocols, and payer decisions about coverage for rehabilitation or scar management services to reduce readmissions and improve value for patients in this DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.